NCT07463898 A Study to Find and Confirm Blood-based Markers (Called Proteins) That May Show Early Heart Changes in Women With Preeclampsia, Even Before Symptoms Appear, and the Use of Heart Ultrasound (Echocardiography) to Look at Patterns of How the Heart Changes During Pregnancy in Women With Preeclampsia
| NCT ID | NCT07463898 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Cardiovascular Biomarkers |
| Study Type | OBSERVATIONAL |
| Enrollment | 172 participants |
| Start Date | 2026-04-24 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 172 participants in total. It began in 2026-04-24 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to find and confirm blood-based markers (called proteins) that may show early heart changes in women with preeclampsia, even before symptoms appear. It will also use heart ultrasound (echocardiography) to look at patterns of how the heart changes during pregnancy in women with preeclampsia. The main questions it aims to answer are: * Do these blood markers relate to heart changes on ultrasound? * How may they help predict future health problems for the mother? Participants will: * Complete a 20-minute survey that will include taking your baseline demographic information, clinical information/medical history, asking about pre-existing health conditions, including measuring your height, weight, and blood pressure. * Have transthoracic echocardiography (TTE) performed at 12 - 16 weeks gestation and again at 28 - 32 weeks gestation. * Provide a blood sample for these protein measurements. These samples will be collected at intake (12 - 16 weeks gestation) and again at 28 - 32 weeks gestation.
Eligibility Criteria
Inclusion Criteria: * • Pregnant women who are up to 20 weeks pregnant * Able to consent to participate in the study * Are enrolled in the ENHANCE-CVH study * Willing to undergo echocardiography and blood draws Exclusion Criteria: * • Known cardiac disease (e.g., cardiomyopathy, coronary artery disease \[CAD\]) * Sickle cell disease * Pulmonary arterial hypertension * Pulmonary embolism * Inability to provide informed consent * Acute Illness * Malignancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07463898 clinical trial?
This trial is open to female participants only, aged 13 Years or older, up to 50 Years, studying Cardiovascular Biomarkers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07463898 currently recruiting?
Yes, NCT07463898 is actively recruiting participants. Contact the research team at zmahmoud@wustl.edu for enrollment information.
Where is the NCT07463898 trial being conducted?
This trial is being conducted at Abuja, Nigeria.
Who is sponsoring the NCT07463898 clinical trial?
NCT07463898 is sponsored by Washington University School of Medicine. The trial plans to enroll 172 participants.